Bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B‑lineage blasts and CD3 on T cells to redirect T‑cell cytotoxicity toward CD19+ cells.
Recombinant bispecific T‑cell engager (BiTE) antibody that binds CD19 on B cells and CD3 on T cells, bringing them together to form an immune synapse and activate T‑cell cytotoxicity (perforin/granzyme release), resulting in targeted lysis of CD19‑positive B‑lineage cells.
YES
DIRECT
Blinatumomab links CD3 on T cells to CD19 on target cells, forming an immune synapse and activating T-cell perforin/granzyme-mediated killing of CD19+ cells.
Bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B‑lineage blasts and CD3 on T cells to redirect T‑cell cytotoxicity toward CD19+ cells.
Recombinant bispecific T‑cell engager (BiTE) antibody that binds CD19 on B cells and CD3 on T cells, bringing them together to form an immune synapse and activate T‑cell cytotoxicity (perforin/granzyme release), resulting in targeted lysis of CD19‑positive B‑lineage cells.
NO
INDIRECT
Blinatumomab binds CD3ε on T cells to activate them; these T cells then kill CD19+ B cells via perforin/granzyme release. CD3ε-expressing T cells are not targeted for killing.
A T-cell-redirecting bispecific antibody (T-cell engager) that binds mesothelin on tumor cells and CD3 on T cells to recruit and activate T cells, inducing cytotoxicity against mesothelin-expressing cancer cells; evaluated as monotherapy with dose escalation and expansion to determine RP2D.
Bispecific antibody that binds mesothelin on tumor cells and CD3 on T cells to recruit and activate cytotoxic T lymphocytes, redirecting them to lyse mesothelin-expressing cancer cells.
YES
DIRECT
Bispecific T-cell engager binds mesothelin on tumor cells and CD3 on T cells, activating CTLs to form an immune synapse and kill mesothelin-expressing cells via perforin/granzyme-mediated cytolysis.
A T-cell-redirecting bispecific antibody (T-cell engager) that binds mesothelin on tumor cells and CD3 on T cells to recruit and activate T cells, inducing cytotoxicity against mesothelin-expressing cancer cells; evaluated as monotherapy with dose escalation and expansion to determine RP2D.
Bispecific antibody that binds mesothelin on tumor cells and CD3 on T cells to recruit and activate cytotoxic T lymphocytes, redirecting them to lyse mesothelin-expressing cancer cells.
NO
INDIRECT
The bispecific antibody engages CD3 on T cells to activate and redirect them to mesothelin-expressing tumor cells; T cells then kill mesothelin+ cells via perforin/granzyme. CD3+ T cells themselves are not killed.
Polyclonal anti-T-cell antibody used for T-cell depletion to reduce rejection and GVHD.
Polyclonal anti-T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated effector functions (e.g., ADCC and phagocytosis), resulting in profound T-cell immunosuppression to reduce rejection and GVHD.
YES
DIRECT
ATG binds CD3ε on T cells and induces complement-dependent lysis and Fc-mediated ADCC/phagocytosis, leading to T-cell depletion.